Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles
Sign Up to like & getrecommendations! Published in 2017 at "Oncoimmunology"
DOI: 10.1080/2162402x.2016.1256527
Abstract: ABSTRACT While RNA-pulsed dendritic cell (DC) vaccines have shown promise, the advancement of cellular therapeutics is fraught with developmental challenges. To circumvent the challenges of cellular immunotherapeutics, we developed clinically translatable nanoliposomes that can be… read more here.
Keywords: rna nps; presenting cells; rna; activation ... See more keywords
COVD-02. ADAPTING RNA-NANOPARTICLE VACCINES FROM GLIOBLASTOMA TO SARS-COV-2
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaa215.087
Abstract: Abstract BACKGROUND Glioblastoma (GBM) can be an effective teacher in the war on COVID-19, as an operative vaccine for either must elicit near-immediate protective responses that overcomes disease heterogeneity and immune suppression. Current prophylactic strategies… read more here.
Keywords: rna nps; immunity; gbm; memory recall ... See more keywords
IMMU-47. RNA-NANOPARTICLE VACCINES ARE SAFE AND IMMUNOLOGICALLY ACTIVE IN CLIENT-OWNED CANINES WITH TERMINAL GLIOMAS
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noz175.539
Abstract: The lack of appropriate preclinical murine glioblastoma models limits comprehensive toxicity/efficacy evaluation of investigational agents. To overcome this challenge, we evaluated the safety and activity of a new immunotherapeutic technology that we have pioneered (composed… read more here.
Keywords: rna nps; rna; client owned; terminal gliomas ... See more keywords
Abstract B83: RNA-nanoparticles for immunotherapy-resistant head and neck squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Cancer immunology research"
DOI: 10.1158/2326-6074.tumimm18-b83
Abstract: Introduction: Immunotherapy is promising for patients with treatment-refractory head and neck squamous cell carcinoma (HNSCC). However, >80% of patients do not respond to checkpoint inhibitors, suggesting that the highly immunosuppressive tumor immune microenvironment of HNSCC… read more here.
Keywords: cell carcinoma; hnscc; squamous cell; rna nps ... See more keywords